GlassScriptPhysician profile
Muhammad Waqas
NPI 1609060334
$102,409.69
in general payments reported to CMS, 2019-2025
34 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $17K · 2021: $11K · 2022: $21K · 2023: $1,713 · 2024: $1,797 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.53 |
| Education | $109.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $43,837.15 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $21,002.18 | 2019-2025 | |
| Abiomed | $11,689.90 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $10,507.80 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $9,706.65 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Abbott Laboratories | $2,045.33 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $1,224.77 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Merck Sharp & Dohme LLC | $404.52 | 2021-2025 | Winrevair, Verquvo |
| Pfizer INC. | $392.23 | 2019-2024 | |
| Medtronic Vascular, INC. | $253.97 | 2019 | |
| Medtronic, INC. | $212.79 | 2021 | |
| Akcea Therapeutics, INC. | $148.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $129.50 | 2022-2025 | Camzyos, Eliquis |
| Getinge USA Sales, LLC | $125.39 | 2019 | |
| Cvrx, INC. | $91.63 | 2024-2025 | Barostim Neo System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $72.19 | 2020 | |
| Amgen INC. | $70.90 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $69.53 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $60.93 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $49.64 | 2020-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.86 | 2019-2020 | |
| Sandoz INC. | $37.60 | 2019 | |
| Boston Scientific Corporation | $32.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $28.62 | 2020-2023 | Xarelto |
| Silk Road Medical, INC. | $26.94 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Atricure, INC. | $19.70 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Solventum Corporation | $18.41 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Johnson & Johnson Health Care Systems INC. | $18.39 | 2024 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.03 | 2023 | Lifevest |
| Philips North America LLC | $15.67 | 2024 | (Ck7) Extended Holter |
| Bridgebio Pharma, INC. | $15.17 | 2025 | Attruby |
| Novo Nordisk INC | $14.31 | 2024 | Ozempic, Rybelsus |
| Cmp Pharma, INC. | $14.22 | 2023 | Carospir |
| Scpharmaceuticals INC. | $13.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Waqas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.